FAK/PYK2 inhibitors defactinib and VS-4718 enhance immune checkpoint inhibitor efficacy

類似資料

• PYK2/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma
  著者:: Muz, Barbara, 等
  出版事項: (2019)
• Merlin deficiency predicts for FAK inhibitor sensitivity: A synthetic lethal relationship
  著者:: Shapiro, Irina M., 等
  出版事項: (2014)
• Targeting focal adhesion kinase reprograms the pancreatic tumor microenvironment and renders pancreas cancer responsive to checkpoint immunotherapy
  著者:: Jiang, Hong, 等
  出版事項: (2015)
• Initial Testing of VS-4718, a novel inhibitor of Focal Adhesion Kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program
  著者:: Kurmasheva, Raushan T., 等
  出版事項: (2016)
• Tumor kinetics prior to treatment correlate with response to checkpoint inhibitors
  著者:: Cadena, Alexandra P, 等
  出版事項: (2015)